CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Samsung Bioepis Co., Ltd. vs. Regeneron Pharmaceuticals, Inc.

๐Ÿ“ก 5G SEP โ€ข ETSI Declared

Explore the PTAB proceeding IPR2025-00176 filed by Samsung Bioepis Co., Ltd. on 2024-11-20. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2025-00176

Filing Date

2024-11-20

Accorded Filing Date

2024-11-20

Institution Decision Date

2025-06-02

Last Modified Date

2025-08-18

Proceeding Type

IPR

Termination Date

2025-06-02

Trial Status

Institution Denied

Parties & Counsel

Patent Owner / Respondent

Patent Information

1 Patent Involved
Respondent Application Number 16739559
Respondent Patent Number 11084865
Legal Expiration Date
2040-01-10 Active (13.1 yrs remaining)
Injunction Viability (35 U.S.C. ยง 283) Active Threat
Respondent Inventor Eric FURFINE et al
Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Tribunal & APJ Panel Intelligence

Board Intelligence

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Decisions Rendered

1 Total

Proceeding Status

Institution Denied

Board Decisions & Rulings (1)

Institution Denied 2025-06-02
Institution Decision: Deny
35 USC 311, 35 USC 314

Address and Attorney/Agent Information

23 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name A&P - Regeneron (Prosecution)
Customer Number 191459
Address 601 Massachusetts Ave., NW, Washington, DC, 20001-3743, UNITED STATES

Attorney / Agent Information

Reg # Name Phone
41408 David Marsh +1 202-942-5068
48001 Thomas Triolo +1 914-847-1612
48921 Stephen Gaudet +1 914-847-7376
50370 Neil Miyamoto +1 914-847-7175
50437 Frank Cottingham +1 914-593-1116
58583 Brian Cocca +1 914-847-1421
58714 Ilona Gont +1 914-847-1304
59668 Brandon Schurter +1 914-847-7000

Global Patent Family Cross-Litigation Radar

CasLoc 360ยฐ Radar 12 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

๐Ÿ‡บ๐Ÿ‡ธ
U.S. District Courts 2 proceedings
๐Ÿ›๏ธ
USPTO PTAB Trials 6 proceedings
๐Ÿ‡ช๐Ÿ‡บ
Unified Patent Court (UPC) Counterparts in force
๐Ÿ‡ฉ๐Ÿ‡ช
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (12): ๐Ÿ‡บ๐Ÿ‡ธ US
Parallel Proceedings Across Jurisdictions (8 found):
PTAB: 6 U.S. Courts: 2
USPTO PTAB Trial 2025-07-14
IPR2025-01268

Fresenius Kabi SwissBioSim GmbH et al. v. Regeneron Pharmaceuticals, Inc.

Asserted Patent
Status: Discretionary Denial
USPTO PTAB Trial 2025-01-15
IPR2025-00456

Celltrion, Inc. v. Regeneron Pharmaceuticals, Inc.

Asserted Patent
Status: Discretionary Denial
USPTO PTAB Trial 2024-12-02
IPR2025-00233

Formycon AG v. Regeneron Pharmaceuticals, Inc.

Asserted Patent
Status: Institution Denied
USPTO PTAB Trial 2023-08-18
IPR2023-01312

Samsung Bioepis Co., Ltd. v. REGENERON PHARMACEUTICALS, INC.

U.S. Continuation Sibling (10464992)
Status: Terminated-Adverse Judgment
USPTO PTAB Trial 2023-01-17
IPR2023-00462

Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (10464992)
Status: Terminated-Adverse Judgment
USPTO PTAB Trial 2021-01-07
IPR2021-00402

Chengdu Kanghong Biotechnology Co., Ltd. et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (10464992)
Status: Terminated
U.S. District Court 2024-05-17
1:24-cv-00053

Regeneron Pharmaceuticals, Inc. v. Celltrion, Inc.

Asserted Patent
Status: WVND
U.S. District Court 2023-11-21
1:23-cv-00094

Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis, CO., LTD.

Asserted Patent
Status: WVND
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Standard Essential Patent (SEP) & FRAND Intelligence

5G SEP โ€ข ETSI Declared High-Probability SEP Action

Essential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation

FRAND Encumbered
Essential Standard 5G NR Generation: 5G
Standard Setting Org (SSO) ETSI / 3GPP Essential specification under ETSI / 3GPP governance
FRAND Commitment Committed Fair, Reasonable & Non-Discrim.
Known Patent Pools Avanci / Sisvel / Via Licensing Coverage Applicable Declarant: Samsung

Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)

Permanent Injunction Restricted

Asserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.

โœ“ Patentee bound by SSO IPR Policy (ETSI Annex 6 / IEEE Patent Policy).
โœ“ Right to demand global FRAND portfolio determination.
โœ“ Non-discrimination defense: check licensing terms offered to competing implementers.

Proceeding Documents

178
14

Notice: refund approved NOTICE

2025-08-18 FILING PARTY: BOARD
13

Request for Refund OTHER

2025-08-15 FILING PARTY: PETITIONER
12

Institution Decision: Deny DECISION

2025-06-02 FILING PARTY: BOARD
2035

Email from D. Berl to District Court Exhibit

2025-05-07 FILING PARTY: PATENT OWNER
11

PATENT OWNERโ€™S SURREPLY IN SUPPORT OF PRELIMINARY RESPONSE OTHER

2025-05-07 FILING PARTY: PATENT OWNER

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc